Abstracts Archive - Page 1168 of 2425 - ACR Meeting Abstracts

Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Susan M. Goodman¹, Bo Shopsin², Allina A. Nocon¹, Andy O. Miller³, Michael W. Henry³, Sarah E. Grond¹, Elianna Kaplowitz¹, Thomas P. Sculco⁴, Linda A. Russell³, Laura T. Donlin⁵, Mark P. Figgie⁴ and Peter K. Sculco⁴, ¹Hospital for Special Surgery, New York, NY, ²Medicine and Microbiology, New York University School of Medicine, New York, NY, ³Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
Abstract Number: 2454 • 2018 ACR/ARHP Annual Meeting
Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
Yukitomo Urata, Rheumatology, Tsugaru General Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan
Background/Purpose: Although the increase in the incidence of Herpes Zoster by tofacitinib(TOF) in rheumatoid arthritis (RA) is well known, the reactivation rate of other viruses…
Abstract Number: 2455 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Judith Maro¹, Talia Menzin², Kenneth Hornbuckle³, Jon T. Giles⁴, Arthur Kavanaugh⁵, Thomas Dörner⁶, David Martin⁷, Jane Huang¹ and Claudia A. Salinas³, ¹Harvard Medical School, Boston, MA, ²Harvard Pilgrim Health Center, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Columbia University, New York, NY, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Food and Drug Administration, Indianapolis, IN
Background/Purpose: Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with…
Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Claudia A. Salinas¹, Lucy Mitchell², Jon T. Giles³, Thomas Dörner⁴ and Stephen P. Motsko¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapols, IN, ³Columbia University, College of Physicians and Surgeons, New York, NY, ⁴Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
Abstract Number: 2457 • 2018 ACR/ARHP Annual Meeting
Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³CaRE Arthritis, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Inflammatory arthritis (IA) is a chronic disorder that encompasses rheumatoid and psoriatic arthritis. Rheumatoid cachexia is defined as elevated HDL, increased adiposity, and loss…
Abstract Number: 2458 • 2018 ACR/ARHP Annual Meeting
Predictors of Hypogammaglobulinemia during Rituximab Maintenance Therapy in Rheumatoid Arthritis: A 12-Year Longitudinal Multi-Center Study
Gonçalo Boleto¹, Jérôme Avouac¹, Julien Wipff¹, Marine Forien², Maxime Dougados³, Christian Roux⁴, André Kahan¹, Philippe Dieude² and Yannick Allanore¹, ¹Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ²Université Paris Diderot, Service de Rhumatologie, Hôpital Bichat, APHP, Paris, France, Paris, France, ³Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, ⁴Université Paris Descartes, Sorbonne Paris Cité, INSERM U1153, Service de Rhumatologie B, Hôpital Cochin, Paris, Paris, France
Background/Purpose: Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and…
Abstract Number: 2459 • 2018 ACR/ARHP Annual Meeting
Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
William Murray-Brown¹, Helen Weedon¹, Tom Wilsdon², Susanna Proudman³, Jenny Walker¹, Malcolm D. Smith⁴ and Mihir D Wechalekar^1,5, ¹Rheumatology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders Medical Centre, Adelaide, Australia, ³Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁴Rheumotology, Flinders University, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Checkpoint inhibitors (CI) for cancer therapy are associated with inflammation that can recapitulate features of autoimmunity, including synovitis resembling rheumatoid arthritis (RA). No reports…
Abstract Number: 2460 • 2018 ACR/ARHP Annual Meeting
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Yoshihiko Ikeno¹, Youkou Kobayashi², Ikuo Akutsu³, Hirokuni Hirata⁴, Masafumi Arima⁵ and Kazuhiro Kurasawa⁶, ¹Rheumatology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ²Hematology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ³Respiratory and allergy, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ⁴Respiratory and allergy, Dokkyo Medical University Saitama Medical center, Saitama, Japan, ⁵Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan, ⁶Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) was first reported in 1991. The symptom is known to spontaneously regress after suspending the use of MTX, suggesting its…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
Abstract Number: 2462 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
Francisco Javier Narváez¹, Alejandro Robles Perez², Patricio Luburich³, J Alegre⁴, Milagros Ricse⁵, Carmen Gomez Vaquero⁶, Joan Miquel Nolla⁵ and Maria Molina⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of rituximab (RTX) in the medium- to long-term for the management of progressive rheumatoid arthritis–related interstitial lung disease…
Abstract Number: 2463 • 2018 ACR/ARHP Annual Meeting
Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care
Isabelle Amigues, Department of Medicine, Division of Rheumatology, National Jewish Health, Denver, CO
Reducing Time to Treatment in Patients with Early and Uncontrolled RA: Implementation of a Collaborative and Systems-Based Approach to Improve Access to Care.Background/Purpose: The first…
Abstract Number: 2464 • 2018 ACR/ARHP Annual Meeting
Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
Jorge Florez-Suarez¹, Paul Mendez², Edna Bermudez¹, Paola Coral² and Gerardo Quintana-Lopez^1,3, ¹Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, ²Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, ³School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia
Background/Purpose: Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept…
Abstract Number: 2465 • 2018 ACR/ARHP Annual Meeting
Characterizing Palindromic Symptoms in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
Leah Ellingwood¹, Orit Schieir², Susan J. Bartlett³, Louis Bessette⁴, Carol A Hitchon⁵, Gilles Boire⁶, Glen Hazlewood⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian P. Bykerk¹¹ and Janet E. Pope¹², ¹Department of Internal Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Laval University, Québec, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ⁸University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, University of Western Ontario, London, ON, Canada
Background/Purpose: Palindromic rheumatism (PR) (transient acute attacks of articular and/or periarticular inflammation) may progress to rheumatoid arthritis (RA). How often early RA (ERA) patients report…
Abstract Number: 2466 • 2018 ACR/ARHP Annual Meeting
Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
Mariam Riad¹, Daniel Dunham², Jacquelin R. Chua¹, Theodore Pincus¹, Najia Shakoor¹, Sobia Hassan¹, Joel A. Block¹ and Isabel Castrejón¹, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: Disparities in the initiation of disease modifying anti-rheumatic drugs (DMARDs) in ethnic minorities have been described in rheumatoid arthritis (RA) patients in the US…
Abstract Number: 2467 • 2018 ACR/ARHP Annual Meeting
RAPID3 Is Elevated in 93% of Treatment-Naïve Rheumatoid Arthritis (RA) Patients at Initial Visit Compared to 49% for Erythrocyte Sedimentation Rate (ESR) and 44% for C-Reactive Protein (CRP)
Mariam Riad, Jacquelin R. Chua, Isabel Castrejón and Theodore Pincus, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative measures to assess and monitor patients with rheumatoid arthritis (RA) traditionally have been laboratory tests, such as erythrocyte sedimentation rate (ESR) and C-reactive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].